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Introduction {#sec005}
============

Human rhinovirus (HRV) infection has been associated with the majority of asthma exacerbations in pediatric patients and with frequent loss of symptom control among asthmatic adults \[[@pone.0178096.ref001]--[@pone.0178096.ref003]\]. HRV is a positive-sense, single-stranded picornavirus that is subcategorized into A, B, and C strains, with HRV-A and HRV-C genotypes implicated in most exacerbations \[[@pone.0178096.ref004]\]. The mechanism for the propensity of HRV infection to trigger an asthma exacerbation remains ill-defined.

After 3 years of age, most asthma exacerbations caused by HRV occur in those who are atopic. Moreover, the risk for wheezing with HRV is strongly associated with high levels of total and allergen specific IgE and with the presence of Th2 related airway inflammation prior to an infection \[[@pone.0178096.ref005]--[@pone.0178096.ref007]\]. Some studies suggest that decreased interferon production in response to HRV infection in the setting of Th2 inflammation may contribute to asthma exacerbation \[[@pone.0178096.ref008]\]. For example, HRV infection of cultured asthmatic bronchial epithelial cells induced less type I interferon production and resistance to early apoptosis compared to control cells, and this was associated with increased viral replication \[[@pone.0178096.ref009]\]. Further, decreased production of type I and III interferons in bronchoalveolar lavage cells has been associated with more severe exacerbations in adult asthmatics \[[@pone.0178096.ref010]\]. Yet, a genome-wide expression analysis of HRV-infected primary bronchial epithelial cells did not reveal any significant differences in interferon expression related to asthma \[[@pone.0178096.ref011]\].

Following viral exposure, we postulate that gene expression at the epithelial cell level is the earliest response to HRV that, in turn, initiates and influences subsequent events that influence the clinical outcome. Indeed, the presence of Th2 associated inflammation (e.g., increased levels of FeNO and eosinophil cationic protein \[ECP\]) detected in the asthmatic airway) has been proposed to contribute to HRV-induced asthma exacerbation during seasons of increased allergen exposure \[[@pone.0178096.ref007]\]. Epithelial cells of the asthmatic airway also have an increased number of protease-activating receptors (PAR). The activation of such receptors leads to opening of tight junctions, production of cytokines and chemokines, and degranulation of eosinophils and mast cells \[[@pone.0178096.ref012]\]. Taken together, we hypothesize that the host response to HRV in the asthmatic airway will be different at the time of initial virus exposure and lead to a unique signature of gene expression that will improve our understanding of asthma attacks caused by HRV.

Experimental procedures {#sec006}
=======================

Patient characteristics {#sec007}
-----------------------

The participants included 5 adults with mild asthma (mean age 25 years; range = 20 to 33 years) and 5 non-atopic adults without asthma (mean age 21.4 years; range = 20 to 23 years). They were screened and characterized with respect to lung function, atopy, and their asthmatic status prior to enrollment (results shown in [Table 1](#pone.0178096.t001){ref-type="table"}). Inclusion and exclusion criteria were similar to our previous experimental challenges with HRV-A16 \[[@pone.0178096.ref007]\]. In brief, all asthmatic subjects had physician-diagnosed, mild asthma and used only inhaled bronchodilators for symptom control. Those using inhaled steroids, nasal steroids, cromolyn, nedocromil sodium, ipratropium bromide, or leukotriene modifiers within one month prior to enrollment were excluded, because these medications could alter epithelial cell gene expression and clinical outcome. In keeping with the diagnosis of mild asthma, those who had used oral steroids within 6 weeks prior to enrollment or who were hospitalized or needed treatment in the emergency room for asthma within 3 years of enrollment were excluded. Asthma subjects were also excluded if they had received allergen immunotherapy within the last 3 years or if their ACT score, to judge symptom control during the month before virus inoculation, was less than 19. All asthmatic subjects were atopic as judged by positive skin prick tests (i.e., a response 3 mm greater than a saline control) to common aeroallergens using extracts from Greer Pharmaceuticals (Lenoir, NC). The allergens included dust mite (*D*. *farinae* and *D*. *pteronyssinus*), cockroach, cat, dog, *Alternaria*, *Aspergillus*, *Penicillium*, 7 grass mix, Bermuda grass, Eastern tree mix, and ragweed. Each asthmatic subject had a positive methacholine challenge at a concentration ≤ 16mg/mL.

10.1371/journal.pone.0178096.t001

###### Patient characteristics.

![](pone.0178096.t001){#pone.0178096.t001g}

  Group            Age   Sex   FEV1% Predicted   Total IgE   Skin Tests                               ACT Score
  ---------------- ----- ----- ----------------- ----------- ---------------------------------------- -----------
  **Asthmatics**   20    F     82                726         Dust mite, cat, dog, mold, tree, grass   24
                   25    M     75                623         Dust mite, cat, dog, mold, tree, grass   21
                   33    F     97                1045        Dust mite, tree, grass, ragweed          21
                   26    F     104               1429        Dust mite, cat, dog, tree, grass         22
                   21    M     94                1989        Dust mite, cat, tree, grass, ragweed     23
  **Controls**     20    M     72                18.3                                                 25
                   22    F     104               5.2                                                  25
                   20    F     96                34.9                                                 25
                   23    F     101               23                                                   25
                   22    M     104               42.5                                                 25

Non-asthmatic control subjects were individuals with no history of asthma or allergic disease. They were excluded if they had a positive methacholine challenge test or a positive skin prick test to any of the aeroallergens tested. All subjects (asthmatics and controls) were excluded if 1) they had a positive test for serum neutralizing antibody to HRV-A16, 2) they had chronic heart or lung disease (other than asthma), or 3) other chronic illnesses such as primary or secondary immunodeficiency disorders. They were also excluded if they had a 5 pack/year history of smoking or any smoking within the last 6 months, or symptoms of upper or lower respiratory infection during the 6 weeks prior to virus inoculation. The study was approved by the Institutional Review Board at the University of Virginia, and all participants signed informed consent before enrollment.

Evaluation at enrollment and virus inoculation {#sec008}
----------------------------------------------

Questionnaires focused on each participant's past and present medical history were administered at enrollment along with a physical exam, spirometry, methacholine challenge, and a nasal wash to confirm absence of HRV infection through qPCR and culture. A blood sample was obtained to re-evaluate serum neutralizing antibody to HRV-A16 and a total IgE level. After a 7-day run-in period to monitor baseline values, each participant was inoculated on arrival at a hotel where subjects were isolated in their own room and monitored daily over a 4-day period after inoculation. The inoculation pool of HRV-A16 was prepared according to GMP specifications and approved by the FDA for experimental challenges (IND \# 15162). Each participant was inoculated with a total dose of 300 TCID^50^mL (tissue culture infectious dose 50/ml) after doing a nasal wash at baseline to test for the presence of pre-existing infection with HRV by culture and qPCR.

Study design {#sec009}
------------

The study design and timeline is shown in [Fig 1](#pone.0178096.g001){ref-type="fig"}. Nasal epithelial samples were obtained after nasal washes (to remove mucous) by gentle scraping of the inferior turbinates within each nostril visualized with a head lamp and a Bionix^®^, Toledo, OH. disposable nasal speculum. The scrapings were obtained with an ASI RhinoPro^®^, Arlington Scientific, Inc., Springville, UT. This procedure was done at enrollment (7 days before inoculation (T0)) and at 36 hours after inoculation (T1) in the hotel. A final scraping was obtained 7 days after virus inoculation (T2) during a clinic visit planned at follow-up. RNA extractions from the epithelial cell scrapings were done within 2 hours using the Qiagen AllPrep DNA/RNA Mini Kit^®^, Hilden, Germany. The nasal washes done prior to the nasal scrapings were used to evaluate viral load and were performed as previously described \[[@pone.0178096.ref005], [@pone.0178096.ref013]\].

![Timeline of study.\
RNA-seq analysis was applied to all nasal epithelial samples.](pone.0178096.g001){#pone.0178096.g001}

Upper airway symptoms were assessed daily on diary cards using the modified Jackson criteria to monitor symptoms of rhinorrhea, sneezing, nasal congestion, sore throat, headache, chills/fevers, and watery/itchy eyes using a scale of 1 through 3, with 1 being mild and clearly present and 3 being severe and interfering with activities \[[@pone.0178096.ref014]\]. Lower airway symptoms of cough, shortness of breath, chest discomfort, wheezing, and night awakenings were also reported by participants on diary cards daily throughout the study using the same severity scale.

Bioinformatic RNA-seq data analysis {#sec010}
-----------------------------------

RNA was isolated from the nasal epithelial samples at the University of Virginia and sent to the University of Cincinnati College of Medicine Genomics, Epigenomics, and Sequencing Core for analysis via RNA-seq. Sequence reads were aligned to the reference human genome (hg19) using the TopHat aligner \[[@pone.0178096.ref015]\]. Reads aligning to each known transcript were counted and all follow up analyses were performed using Bioconductor packages for next-generation sequencing data analysis \[[@pone.0178096.ref016]\]. The differential gene expression analysis was performed based on the negative-binomial statistical model of read counts as implemented in the *edgeR* Bioconductor package \[[@pone.0178096.ref017]\]. Genes differentially expressed between asthma and control samples before inoculation (time point T0) were identified using the simple generalized linear model with the single factor (asthma = yes or no). Genes differentially expressed after inoculation (time points T1 and T2) in comparison to the baseline (time point T0) were identified by fitting a generalized linear model with both time and subject factors to account for the subject-to-subject variability. These comparisons were made separately for asthma and control samples. P-values were adjusted for multiple testing using the false discovery rates and differential expressions with FDR-adjusted p-value of less than 0.05 were considered statistically significant \[[@pone.0178096.ref018]\]. To elucidate the most common pathways affected the by gene dysregulation, all genes dysregulated at least 1.5 fold were analyzed with QIAGEN's Ingenuity^®^ Pathway Analysis (IPA^®^, QIAGEN Redwood City, [www.qiagen.com/ingenuity](http://www.qiagen.com/ingenuity)).

Upper and lower respiratory tract symptom score analyses {#sec011}
--------------------------------------------------------

Cumulative upper and lower respiratory tract symptom (CURTS and CLRTS, respectively) scores were derived from diary cards. The CURTS and CLRTS scores were computed by numerically adding up the individual upper and lower respiratory tract symptom scores recorded daily by study participants from day 0 (day of HRV-A16 inoculation) to post-inoculation day 7 (T2). The CURTS and CLRTS scores were analyzed by way of negative binomial generalized linear models. Study-group (i.e. the asthmatic or non-asthmatic group) served as the *independent* variable of each analysis and between-group comparisons were focused on comparing the means of the underlying cumulative symptom score distributions. A two-sided p≤0.05 decision rule was used as the *between* study-group comparison null hypothesis rejection criterion. The software of the PROC GENMOD procedure of SAS version 9.4 (SAS Institute Inc., Cary, NC) was used to conduct the cumulative symptom score analysis.

Results {#sec012}
=======

Tests for atopy, Rhinovirus infection, and symptoms {#sec013}
---------------------------------------------------

The five asthmatic participants in this study had 4 or more positive tests for allergen specific IgE by prick skin testing and high levels of total IgE (geometric mean \[GM\] = 1061 IU/ml; range = 623--1989) ([Table 1](#pone.0178096.t001){ref-type="table"}). The 5 controls had negative skin tests and their total IgE levels were low (GM = 20 IU/ml; range = 5--42). Following virus inoculation, HRV titers in cultures from nasal washes were quantified with average viral titers from T0 to T2 ranging from 0.92 to 1.96 titer/mL from the asthmatics. Three of the five controls had HRV isolated in culture, with average viral titers from T0 to T2 ranging from 1.74 to 2.03 titer/mL. The remaining 2 control subjects did not have positive viral cultures, but they had low levels of HRV-A16 detected through qPCR during the study to confirm successful inoculation. The mean CURTS scores over the 7 days of monitoring after RV inoculation were 65 (34--126, 95% confidence limits \[CL\]) and 32 (16--62, 95% CL) for the asthmatic and non-asthmatic groups, respectively; p = 0.133 ([Fig 2](#pone.0178096.g002){ref-type="fig"}). The mean CLRTS scores over the same time period were 25 (10--64; 95% CL) and 3 (1.0--9; 95% CL) for the asthmatics and non-asthmatic controls, respectively; p = 0.004.

![Mean upper respiratory tract symptom score (A) and mean lower respiratory tract symptom score (B).\
Points identify the mean symptom scores determined (as described in the Methods) on each day (T0, T1, T2) when epithelial cell scrapings were obtained, Vertical lines identify the range of values within ± 1 standard error of the mean total symptom score.](pone.0178096.g002){#pone.0178096.g002}

Differences in gene expression between asthmatics and controls evident at baseline {#sec014}
----------------------------------------------------------------------------------

[Fig 3](#pone.0178096.g003){ref-type="fig"} is an overview of the gene dysregulation in asthmatics and controls at baseline and in response to HRV infection. At baseline, 50 genes were differentially expressed at least 1.5 fold in asthmatics compared to controls ([Table 2](#pone.0178096.t002){ref-type="table"}). Asthmatics had increased expression of genes involved in inflammation, including interleukin-1 receptor, type 1 (*IL1R1*), arachidonate 5-lipoxygenase (*ALOX5*), and tryptase alpha/beta-1 (*TPSAB1*). Additionally, asthmatics had decreased expression of viral replication inhibitors---interferon-induced protein with tetratricopeptide repeats 1 (*IFIT1*) and SAM domain and HD domain-containing protein 1 (*SAMHD1*).

10.1371/journal.pone.0178096.t002

###### Top 30 genes with expression affected at least 3 fold between asthmatics and controls at baseline.
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  geneid         symbol         name                                                                                padj     fold change
  -------------- -------------- ----------------------------------------------------------------------------------- -------- -------------
  **2624**       GATA2          GATA binding protein 2                                                              0.0212   66.3627
  **1359**       CPA3           carboxypeptidase A3 (mast cell)                                                     0.0400   64.8943
  **64499**      TPSB2          tryptase beta 2 (gene/pseudogene)                                                   0.0003   52.4161
  **7177**       TPSAB1         tryptase alpha/beta 1                                                               0.0003   51.6452
  **6422**       SFRP1          secreted frizzled-related protein 1                                                 0.0363   25.5794
  **10631**      POSTN          periostin, osteoblast specific factor                                               0.0472   21.2008
  **2354**       FOSB           FBJ murine osteosarcoma viral oncogene homolog B                                    0.0006   17.3689
  **1958**       EGR1           early growth response 1                                                             0.0212   10.2780
  **2353**       FOS            FBJ murine osteosarcoma viral oncogene homolog                                      0.0212   10.1764
  **4915**       NTRK2          neurotrophic tyrosine kinase, receptor, type 2                                      0.0145   7.3831
  **3164**       NR4A1          nuclear receptor subfamily 4, group A, member 1                                     0.0396   6.3766
  **240**        ALOX5          arachidonate 5-lipoxygenase                                                         0.0212   6.3736
  **9021**       SOCS3          suppressor of cytokine signaling 3                                                  0.0386   6.0078
  **6550**       SLC9A3         solute carrier family 9, subfamily A (NHE3, cation proton antiporter 3), member 3   0.0158   5.9875
  **7832**       BTG2           BTG family, member 2                                                                0.0039   5.4052
  **55107**      ANO1           anoctamin 1, calcium activated chloride channel                                     0.0000   5.1866
  **857**        CAV1           caveolin 1, caveolae protein, 22kDa                                                 0.0212   4.5104
  **7538**       ZFP36          ZFP36 ring finger protein                                                           0.0181   4.0869
  **9245**       GCNT3          glucosaminyl (N-acetyl) transferase 3, mucin type                                   0.0000   4.0763
  **1549**       CYP2A7         cytochrome P450, family 2, subfamily A, polypeptide 7                               0.0341   4.0437
  **56165**      TDRD1          tudor domain containing 1                                                           0.0080   -16.3343
  **1.01E+08**   LOC100996579   uncharacterized LOC100996579                                                        0.0341   -5.6716
  **8647**       ABCB11         ATP-binding cassette, sub-family B (MDR/TAP), member 11                             0.0039   -5.0905
  **285313**     IGSF10         immunoglobulin superfamily, member 10                                               0.0212   -4.4396
  **347**        APOD           apolipoprotein D                                                                    0.0474   -4.2888
  **345930**     ECT2L          epithelial cell transforming 2 like                                                 0.0212   -4.1564
  **2628**       GATM           glycine amidinotransferase (L-arginine:glycine amidinotransferase)                  0.0158   -4.0163
  **23007**      PLCH1          phospholipase C, eta 1                                                              0.0133   -3.8777
  **3434**       IFIT1          interferon-induced protein with tetratricopeptide repeats 1                         0.0084   -3.8357
  **730101**     LOC730101      uncharacterized LOC730101                                                           0.0212   -3.7865

![Dysregulated genes in asthmatic and control subjects.](pone.0178096.g003){#pone.0178096.g003}

Rhinovirus-16 infection results in increased number of dysregulated genes and more persistent gene dysregulation in asthmatics compared to controls {#sec015}
---------------------------------------------------------------------------------------------------------------------------------------------------

As evident in [Fig 3](#pone.0178096.g003){ref-type="fig"}, there is substantial gene dysregulation in response to HRV infection in both asthmatics and controls, but it is stronger and more persistent in asthmatics. Following inoculation with HRV, gene expression was significantly altered at T1 in asthmatics and controls with changes favoring upregulation in both groups. However, the asthmatic group showed significantly more dysregulated genes compared to controls. From T0 to T1, there were 1253 genes dysregulated at least 1.5 fold in asthma participants compared to 59 genes in controls ([Fig 4A](#pone.0178096.g004){ref-type="fig"}). By T2, gene expression in controls had essentially returned to baseline levels with only 4 genes dysregulated at least 1.5 fold compared to baseline expression ([Fig 4B](#pone.0178096.g004){ref-type="fig"}). In contrast, asthmatics continued to have significant gene dysregulation with 178 genes upregulated or downregulated at least 1.5 fold from baseline even 7 days later ([Fig 4B](#pone.0178096.g004){ref-type="fig"}). The gene expression from T0 through T2 in asthmatics and controls were categorized into 9 different clusters ([Fig 5](#pone.0178096.g005){ref-type="fig"}). A total of 1573 genes were found to have at least 1.5 fold change in expression in all participants of the study---asthmatics or controls---and to be significantly dysregulated (p adj \< 0.05). Of this total, 1350 genes were unchanged in controls. Controls had 133 genes that were unchanged from T0 to T1 that then were downregulated from T1 to T2; 31 genes were upregulated from T0 to T1 and then were unchanged from T1 to T2. Asthmatics, on the other hand, had only 295 genes that were unchanged from T0 through T2. 670 genes were upregulated from T0 to T1 and were unchanged from T1 to T2 in asthmatics; 412 genes were upregulated from T0 to T1 and then downregulated from T1 to T2. This cluster analysis further illustrates the increased magnitude and persistence of gene dysregulation in asthmatics compared to controls in response to HRV infection.

![A. Heat map illustrating gene dysregulation in controls (left) and asthmatics (right) at T1 versus T0. The baseline samples of one asthmatic and one control patient were not of sufficient quality and were not included in analysis. The sample from T1 of one asthmatic was not of sufficient quality and was also excluded. B. Heat maps illustrating gene dysregulation in controls (left) and asthmatics (right) at T2 versus T0. The normalized RNA-seq raw counts for SPINK5 in controls at baseline and at T2 ranged from 2.6 to 35.3 and are reflected in the heat map with green representing lower values and red representing higher values.](pone.0178096.g004){#pone.0178096.g004}

![Cluster analysis of gene expression asthmatics (red) and controls (blue).\
A total of 1573 genes had at least 1.5 fold change in controls or asthmatics with significant dysregulation (p adj \< 0.05). 1350 of these genes were unchanged in controls. 295 of these genes were unchanged in asthmatics. 670 genes were upregulated from T0 to T1 and unchanged from T1 to T2 in asthmatics. 412 genes were upregulated from T0 to T1 and downregulated from T1 to T2 in asthmatics.](pone.0178096.g005){#pone.0178096.g005}

The biology of the response to Rhinovirus-16 infection is different in asthmatics compared to controls {#sec016}
------------------------------------------------------------------------------------------------------

We next more carefully examined the differences in the biologic response to HRV-A16 in asthmatics versus controls. Tables [3](#pone.0178096.t003){ref-type="table"}--[6](#pone.0178096.t006){ref-type="table"} list the 30 most dysregulated genes in asthmatics and controls at T1 versus T0 and T2 versus T0 (complete listing of dysregulated genes is detailed in [S1 File](#pone.0178096.s001){ref-type="supplementary-material"}). Pathway analyses revealed that most of the dysregulation in both asthmatics and controls involves the innate and early adaptive immune response to HRV infection including IL-6 signaling \[*FOS*, *IL18RAP*, *IL1B*, and *JUN*\], dendritic cell maturation \[including *ICAM1*, *IL1RN*, *JAK2*, *STAT1*,*STAT4*, *TNF*, *TLR2*, *TLR4*, *NFKB2*, and *PIK3R5*\], granulocyte adhesion/diapedesis \[including *ICAM1*, *ITGB2*, *CCL3L1*, *CCL3L3*, *CXCL1*, *MMP2*, *MMP13*, *C5AR1*, *CLDN10*, and *CXCR4*\], interferon signaling \[*STAT1*, *JAK2*, *IFIT1*, *IFIT3*, *IFITM1*, *IFITM2*, *IFITM3*, *OAS1*, and *TAP1*\], and B-cell development \[including *CD19*, *IL7R*, *CD86*, *PTPRC*, *HLA-DMA*, *HLA-DMB*, *HLA-DOA*, *HLA-DQA*, *HLA-DRA*, and *HLA-DRB1*\]. There were several notable differences between asthmatics and controls. The regulatory IL-10 pathway was upregulated in controls at T1, with significant increase in expression of *SOCS3*, a suppressor of cytokine signaling. This increase in IL-10 signaling was not evident in asthmatics at T1 or T2. Also, in controls, *SPINK5*, which has been implicated in epithelial maintenance and repair, was induced 5.3 fold at T2 compared to baseline expression. This increase in SPINK5 was not evident in asthmatics.

10.1371/journal.pone.0178096.t003

###### Genes with expression affected at least 3 fold in control group from T0 to T1.
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  geneid       symbol    name                                                                                    padj       fold change
  ------------ --------- --------------------------------------------------------------------------------------- ---------- -------------
  **4060**     LUM       lumican                                                                                 0.020943   72.8022
  **342510**   CD300E    CD300e molecule                                                                         0.008487   38.3880
  **3553**     IL1B      interleukin 1, beta                                                                     0.003612   21.7846
  **1278**     COL1A2    collagen, type I, alpha 2                                                               0.000348   21.7134
  **414062**   CCL3L3    chemokine (C-C motif) ligand 3-like 3                                                   0.026042   17.5723
  **6349**     CCL3L1    chemokine (C-C motif) ligand 3-like 1                                                   0.026042   17.5723
  **1960**     EGR3      early growth response 3                                                                 0.0124     12.4203
  **5329**     PLAUR     plasminogen activator, urokinase receptor                                               0.033343   9.6363
  **1959**     EGR2      early growth response 2                                                                 0.048586   9.2946
  **4313**     MMP2      matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)   0.00553    7.4013
  **1289**     COL5A1    collagen, type V, alpha 1                                                               0.043756   7.2466
  **9021**     SOCS3     suppressor of cytokine signaling 3                                                      1.27E-06   7.1697
  **64092**    SAMSN1    SAM domain, SH3 domain and nuclear localization signals 1                               0.026322   7.1446
  **2353**     FOS       FBJ murine osteosarcoma viral oncogene homolog                                          0.022499   6.7704
  **6503**     SLA       Src-like-adaptor                                                                        0.017101   6.2597
  **5999**     RGS4      regulator of G-protein signaling 4                                                      0.012113   5.8468
  **5788**     PTPRC     protein tyrosine phosphatase, receptor type, C                                          0.030499   5.2359
  **84913**    ATOH8     atonal homolog 8 (Drosophila)                                                           0.007565   4.2610
  **8807**     IL18RAP   interleukin 18 receptor accessory protein                                               0.012113   4.2399
  **133**      ADM       adrenomedullin                                                                          0.009749   3.8967
  **51297**    BPIFA1    BPI fold containing family A, member 1                                                  0.005879   3.8852
  **11151**    CORO1A    coronin, actin binding protein, 1A                                                      0.012414   3.8204
  **1907**     EDN2      endothelin 2                                                                            0.015707   3.8022
  **92304**    SCGB3A1   secretoglobin, family 3A, member 1                                                      2.08E-08   3.6013
  **7538**     ZFP36     ZFP36 ring finger protein                                                               0.012292   3.3842
  **4322**     MMP13     matrix metallopeptidase 13 (collagenase 3)                                              0.12414    3.2228
  **7031**     TFF1      trefoil factor 1                                                                        0.001698   3.0703

10.1371/journal.pone.0178096.t004

###### Top 30 genes with expression affected at least 3 fold in asthmatics from T0 to T1.
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  geneid          symbol      name                                                                          padj          fold change
  --------------- ----------- ----------------------------------------------------------------------------- ------------- --------------
  **3552**        IL1A        interleukin 1, alpha                                                          1.71E-05      28.92492495
  **402665**      IGLON5      IgLON family member 5                                                         0.002964315   26.55078527
  **719**         C3AR1       complement component 3a receptor 1                                            4.17E-05      26.09216702
  **4973**        OLR1        oxidized low density lipoprotein (lectin-like) receptor 1                     0.000737414   25.21195402
  **6373**        CXCL11      chemokine (C-X-C motif) ligand 11                                             2.34E-10      22.43688977
  **4064**        CD180       CD180 molecule                                                                0.038699948   21.74115708
  **23601**       CLEC5A      C-type lectin domain family 5, member A                                       0.000460589   20.90985398
  **6347**        CCL2        chemokine (C-C motif) ligand 2                                                0.001554308   20.54486259
  **2865**        FFAR3       free fatty acid receptor 3                                                    1.65E-05      18.54119076
  **101928513**   CATIP-AS1   CATIP antisense RNA 1                                                         0.005560741   15.54512675
  **5806**        PTX3        pentraxin 3, long                                                             1.99E-07      14.73660174
  **6351**        CCL4        chemokine (C-C motif) ligand 4                                                3.02E-10      13.67747639
  **160622**      GRASP       GRP1 (general receptor for phosphoinositides 1)-associated scaffold protein   0.008466801   13.67246691
  **9560**        CCL4L2      chemokine (C-C motif) ligand 4-like 2                                         7.20E-07      13.43126991
  **388372**      CCL4L1      chemokine (C-C motif) ligand 4-like 1                                         9.04E-07      13.33820322
  **5329**        PLAUR       plasminogen activator, urokinase receptor                                     7.87E-08      13.28421895
  **10578**       GNLY        granulysin                                                                    0.04395143    12.75855934
  **221692**      PHACTR1     phosphatase and actin regulator 1                                             0.016054301   12.71174252
  **3576**        CXCL8       chemokine (C-X-C motif) ligand 8                                              1.35E-09      12.70191061
  **3575**        IL7R        interleukin 7 receptor                                                        2.51E-05      12.57533077
  **10563**       CXCL13      chemokine (C-X-C motif) ligand 13                                             0.041383665   12.1909315
  **56165**       TDRD1       tudor domain containing 1                                                     0.000775926   12.09246229
  **100128385**   FAM225B     family with sequence similarity 225, member B (non-protein coding)            0.030859801   11.91060151
  **8013**        NR4A3       nuclear receptor subfamily 4, group A, member 3                               0.001564312   11.82961672
  **7772**        ZNF229      zinc finger protein 229                                                       0.046632528   11.7866035
  **1493**        CTLA4       cytotoxic T-lymphocyte-associated protein 4                                   0.033675632   11.71145859
  **400680**      LINC00664   long intergenic non-protein coding RNA 664                                    2.79E-06      11.59893421
  **23769**       FLRT1       fibronectin leucine rich transmembrane protein 1                              0.003228573   -23.25413453
  **25787**       DGCR9       DiGeorge syndrome critical region gene 9 (non-protein coding)                 0.020863424   -18.17084882
  **152**         ADRA2C      adrenoceptor alpha 2C                                                         0.002794832   -13.37477796

10.1371/journal.pone.0178096.t005

###### Genes with expression affected at least 3 fold in control group from T0 to T2.
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  geneid      symbol   name                                           padj       fold change
  ----------- -------- ---------------------------------------------- ---------- -------------
  **84913**   ATOH8    atonal homolog 8 (Drosophila)                  0.034015   3.796982
  **6035**    RNASE1   ribonuclease, RNase A family, 1 (pancreatic)   0.018146   5.157555
  **11005**   SPINK5   serine peptidase inhibitor, Kazal type 5       1.51E-08   5.268909

10.1371/journal.pone.0178096.t006

###### Top 30 Genes with expression affected at least 3 fold in asthmatics from T0 to T2.

![](pone.0178096.t006){#pone.0178096.t006g}

  geneid          symbol         name                                                                   padj          fold change
  --------------- -------------- ---------------------------------------------------------------------- ------------- -------------
  **10578**       GNLY           granulysin                                                             0.023905745   19.41766265
  **5079**        PAX5           paired box 5                                                           0.024519067   18.71066511
  **2537**        IFI6           interferon, alpha-inducible protein 6                                  5.10E-06      15.51483751
  **4283**        CXCL9          chemokine (C-X-C motif) ligand 9                                       0.043209055   8.507631831
  **5551**        PRF1           perforin 1 (pore forming protein)                                      0.024519067   7.640101617
  **91543**       RSAD2          radical S-adenosyl methionine domain containing 2                      9.98E-12      7.566978504
  **3434**        IFIT1          interferon-induced protein with tetratricopeptide repeats 1            0.024776552   7.008492872
  **10964**       IFI44L         interferon-induced protein 44-like                                     0.001195079   5.75513534
  **6362**        CCL18          chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated)   0.0162948     5.623785255
  **9636**        ISG15          ISG15 ubiquitin-like modifier                                          7.68E-05      5.215923291
  **5653**        KLK6           kallikrein-related peptidase 6                                         0.019548496   4.868135902
  **129607**      CMPK2          cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial               0.002773796   4.741074774
  **3437**        IFIT3          interferon-induced protein with tetratricopeptide repeats 3            0.002006977   4.276974551
  **710**         SERPING1       serpin peptidase inhibitor, clade G (C1 inhibitor), member 1           0.000537538   4.177324231
  **79931**       TNIP3          TNFAIP3 interacting protein 3                                          0.000432613   4.105550274
  **80320**       SP6            Sp6 transcription factor                                               0.02127551    4.077235267
  **27074**       LAMP3          lysosomal-associated membrane protein 3                                0.008830902   3.862185131
  **348**         APOE           apolipoprotein E                                                       4.41E-06      3.846620987
  **7453**        WARS           tryptophanyl-tRNA synthetase                                           0.000534318   3.822353718
  **100126311**   MIR147B        microRNA 147b                                                          4.68E-18      3.652618463
  **8771**        TNFRSF6B       tumor necrosis factor receptor superfamily, member 6b, decoy           0.000551508   3.643040835
  **3433**        IFIT2          interferon-induced protein with tetratricopeptide repeats 2            0.003161937   3.640824157
  **4481**        MSR1           macrophage scavenger receptor 1                                        0.013181546   3.578676195
  **641517**      DEFB109P1B     defensin, beta 109, pseudogene 1B                                      0.030905088   -27.09924
  **284654**      RSPO1          R-spondin 1                                                            0.006456265   -5.278907
  **101927560**   LOC101927560   uncharacterized LOC101927560                                           4.11E-05      -4.316873
  **100616209**   MIR4461        microRNA 4461                                                          7.68E-05      -4.285838
  **128102**      HSD3BP4        hydroxy-delta-5-steroid dehydrogenase, 3 beta, pseudogene 4            0.002899914   -4.12954
  **1592**        CYP26A1        cytochrome P450, family 26, subfamily A, polypeptide 1                 0.000130986   -3.80011
  **102465432**   MIR6723        microRNA 6723                                                          0.027519068   -3.601905

Discussion {#sec017}
==========

Our data demonstrate that the biology of the host response to HRV is fundamentally different in asthmatics compared to controls with striking differences in epithelial cell gene expression during the early, innate phase of the infection before symptoms peak. Asthmatics demonstrated increased magnitude and persistence of gene dysregulation, as well as distinct differences in the quality of the response following infection with HRV-A16 ([Fig 6](#pone.0178096.g006){ref-type="fig"}).

![Summary of gene dysregulation in asthmatics versus controls from T0 to T2 (left) and summary of differences in innate immunity, including the epithelial barrier (right).\
These differences may contribute to increased magnitude and persistence of gene dysregulation in asthmatics in response to HRV infection.](pone.0178096.g006){#pone.0178096.g006}

Consistent with reports that increased levels of inflammatory biomarkers are detected in the upper and lower airway of asthmatics before an experimental challenge with HRV \[[@pone.0178096.ref007]\], baseline differences in gene expression associated with inflammatory pathways were also significantly increased among the asthmatics compared to the controls. These baseline differences may contribute to an increased susceptibility to viral infection in keeping with the observation that asthmatics had decreased expression of viral replication inhibitors compared to controls. We observed in asthmatics increased expression of genes involved in inflammation---interleukin-1 receptor, type 1 (*IL1R1*), arachidonate 5-lipoxygenase (*ALOX5*), and tryptase alpha/beta-1 (*TPSAB1*). Tryptase is an activator of PAR-2, which in turn causes weakening of tight junctions within the epithelial layer, allowing for easier access to receptors used by HRV to infect epithelial cells and contributing to the severity and persistence of symptoms \[[@pone.0178096.ref012], [@pone.0178096.ref019]\].

As with prior studies, gene expression in both asthmatics and controls skewed towards activation of the innate and early adaptive immune response, including interferon signaling and granulocyte adhesion/diapedesis, after HRV inoculation \[[@pone.0178096.ref020]\]. Additionally, pathway analysis showed an early emergence of IL-10 signaling pathway in the control group from T0 to T1, which was absent in the asthmatic group from T0 to T1 and even from T0 to T2. While nasal mucosal samples do not exclude infiltrating cells such as monocytes, a major producer of IL-10, Guajardo et al has previously shown that such samples are composed mainly (\> 92%) of respiratory epithelial cells \[[@pone.0178096.ref021]\]. IL-10 is a regulatory cytokine with dominant immunosuppressive effects resulting in inhibition of IL-12 production, reduced expression of co-stimulatory molecules and Class I MHC, suppression of production of pro-inflammatory cytokines including IL-2, TNF-alpha, and IL-5, and increased production of anti-inflammatory cytokines including IL-1Ralpha and VEGF \[[@pone.0178096.ref022]\]. Indeed, impaired IL-10 responses have been associated with HRV-induced asthma exacerbations \[[@pone.0178096.ref023]\]. Further, several studies have shown that polymorphisms in the IL-10 promoter are associated with asthma, possibly due to decreased IL-10 production \[[@pone.0178096.ref024]--[@pone.0178096.ref028]\].

Although the asthmatics had markedly persistent gene dysregulation following HRV infection, there were a few genes that were notably induced during the convalescent recovery phase (T2) in control subjects. One of 4 genes that was induced in controls at T2 compared to baseline was *SPINK5*, which has been intensely studied in asthma due to its location within chromosome 5q31-33, a region shown in genome-wide linkage scans to be linked to asthma and atopy \[[@pone.0178096.ref029]\]. *SPINK5* encodes an inhibitor of multiple serine proteases, including plasmin, neutrophil elastase, and trypsin, and mutations in this gene have been associated with Netherton syndrome \[[@pone.0178096.ref029]\]. *SPINK5* polymorphisms/haplotypes have also been associated with asthma susceptibility in numerous populations \[[@pone.0178096.ref030]--[@pone.0178096.ref032]\]. The upregulation of *SPINK5* in controls at T2 suggests it may be important in epithelial repair. While a recent study involving the transfection of A549 cells (adenocarcinomic human alveolar basal epithelial cells) with SPINK5 expression vectors resulted in increased production of IL-6, IL-8, and RANTES, transfection also resulted in increased susceptibility to cell death \[[@pone.0178096.ref033]\]. As destruction of infected cells is key for antigen presentation in the immune response to active viral infections, increased *SPINK5* expression may be a protective measure. Additionally, studies measuring SPINK5 in nasal epithelial tissue revealed that low SPINK5 expression was associated with chronic rhinosinusitis with and without nasal polyps \[[@pone.0178096.ref034]\] and among those with chronic rhinosinusitis and aspirin intolerance \[[@pone.0178096.ref035]\]. The association between atopic diseases and polymorphisms or decreased expression of *SPINK5* suggests a significant role for this protease inhibitor in epithelial cell maintenance and repair.

The RV challenge model has been helpful in other investigations to explore mechanistic questions focused on the asthmatic response to RV \[[@pone.0178096.ref011], [@pone.0178096.ref023], [@pone.0178096.ref036]--[@pone.0178096.ref038]\]. To our knowledge, however, this is the first report of changes in gene expression in response to HRV observed well before symptoms peak among asthmatics who, in our study, experienced more significant lower respiratory tract symptoms and sustained gene expression that was still augmented compared to the non-asthmatics 7 days after virus inoculation. Our study was limited by a small sample size, and the gene expression analysis could not be completed for two participants---one control and one asthmatic---due to samples of insufficient quality. Because of the broad inclusion and exclusion criteria required to find subjects who are eligible for participation, it is difficult to enroll larger numbers of mild asthmatics who are seronegative to the strain of virus used for inoculation and who are not using controller medications in these studies. However, the dysregulation of genes noted at 36 hours, and the persistent changes at 7 days, was striking among the asthmatics and these results are unlikely to be altered by including data from more subjects. For example, epithelial cell gene expression has been examined in response to HRV-A16 in nasal scrapings from healthy, non-asthmatic subjects who tested positive for HRV in cultures of their nasal washes. As compared to the 1263 genes dysregulated at least 1.5 fold among the asthmatics in our study, significantly fewer genes were dysregulated in nasal scrapings at 48 hours in that study (i.e., 471 genes showed a ≥ 2-fold increase in gene expression and 201 genes decreased ≥ 0.5-fold) \[[@pone.0178096.ref039]\]

In the future, further studies would be desirable to examine gene expression in epithelial cell samples obtained at earlier time points after HRV inoculation. A longer follow-up period (e.g., 3 to 4 weeks after inoculation) would also be beneficial to determine how long the gene dysregulation in asthmatics persists and to evaluate any differences in relation to the adaptive immune response. Additionally, the enrollment of atopic subjects without asthma would be of interest, along with selected samples collected for gene expression analysis from the lower airway.

In summary, asthmatics have a substantially altered host response to HRV-A16 infection in terms of magnitude, quality, and persistence when compared to non-asthmatic controls. Differences in gene expression were apparent at baseline, during infection, and during the onset of convalescence/repair. At baseline, increased expression of inflammatory genes and decreased expression of viral replication inhibitors was evident in asthmatics, and emergence of IL-10 signaling early in infection was evident only in controls. During convalescence/repair, upregulation of *SPINK5* was seen only in controls underscoring the role of this protease inhibitor in the recovery phase. These key differences provide novel mechanistic insights into how HRV infection may contribute to asthma exacerbation and highlight previously unrecognized pathways that may be important targets for therapeutic intervention.

Supporting information {#sec018}
======================

###### Complete list of dysregulated genes.

This excel workbook details the complete list of dysregulated genes in both asthmatics and controls.

(XLSX)

###### 

Click here for additional data file.
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